nach oben

Drugs

Erschienen in:

01.10.2013 | Adis Drug Evaluation

Fidaxomicin: A Review of Its Use in Patients with Clostridium difficile Infection

verfasst von: Lesley J. Scott

Erschienen in: Drugs | Ausgabe 15/2013

Einloggen, um Zugang zu erhalten

Abstract

Oral fidaxomicin (Dificid^®; Dificlir^®) is a first-in-class macrocyclic antibacterial that is approved in several countries for the treatment of adult patients with Clostridium difficile-associated diarrhoea. Fidaxomicin 200 mg twice daily for 10 days was an effective and generally well tolerated treatment in adult patients with a first episode or first recurrence of C. difficile infection. In two multinational phase III trials, fidaxomicin treatment was noninferior to vancomycin treatment with regard to clinical cure rates and was associated with statistically significantly lower C. difficile infection recurrence rates and statistically significantly higher global cure rates than vancomycin. The drug has a favourable pharmacological profile, including having a narrow spectrum of activity that targets relevant pathogens, minimal impact on normal faecal microflora, a convenient treatment regimen and attainment of very high faecal concentrations. Albeit further clinical experience is required to fully define the position of fidaxomicin, it is a valuable emerging option for the treatment of first episode and recurrent episodes of C. difficile-associated diarrhoea.

Johnson AP, Wilcox MH. Fidaxomicin: a new option for the treatment of Clostridium difficile infection. J Antimicrob Chemother. 2012;67(12):2788–92.PubMedCrossRef

Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431–55.PubMedCrossRef

Cecil JA. Clostridium difficile: changing epidemiology, treatment and infection prevention measures. Curr Infect Dis Rep. 2012;14:612–9.PubMedCrossRef

Drekonja DM, Butler M, MacDonald R, et al. Comparative effectiveness of Clostridium difficile treatments: a systematic review. Ann Intern Med. 2011;155(12):839–47.PubMedCrossRef

O’Horo JC, Jindai K, Kunzer B, et al. Treatment of recurrent Clostridium difficile infection: a systematic review. Infection. 2013. doi:10.1007/s15010-013-0496-x.PubMed

Khanna S, Pardi DS. Clostridium difficile infection: new insights into management. Mayo Clin Proc. 2012;87(11):1106–17.PubMedCrossRef

Cornely OA. Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin? Clin Microbiol Infect. 2012;18(Suppl 6):28–35.PubMedCrossRef

Sears P, Ichikawa Y, Ruiz N, et al. Advances in the treatment of Clostridium difficile infection with fidaxomicin: a narrow spectrum antibiotic. Ann NY Acad Sci. 2013;1291(1):33–41.PubMedCrossRef

Debast SB, Bauer MP, Kuijper EJ. On behalf of the European Society of Clinical Microbiology and Infectious Diseases Committee. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): update of the treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect. 2013. doi:10.1111/1469-0691.12418.

10.

Duggan ST. Fidaxomicin: in Clostridium difficile infection. Drugs. 2011;71(18):2445–56.PubMedCrossRef

11.

Theriault RJ, Karwowski JP, Jackson M, et al. Tiacumicins, a novel complex of 18-membered macrolide antibiotics: I. Taxonomy, fermentation and antibacterial activity. J Antibiot (Tokyo). 1987;40(5):567–74.CrossRef

12.

Finegold SM, Molitoris D, Vaisanen ML, et al. In vitro activities of OPT-80 and comparator drugs against intestinal bacteria. Antimicrob Agents Chemother. 2004;48(12):4898–902.PubMedCrossRef

13.

Citron DM, Tyrrell KL, Merriam CV, et al. Comparative in vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria. Antimicrob Agents Chemother. 2012;56(5):2493–503.PubMedCrossRef

14.

Hecht DW, Galang MA, Sambol SP, et al. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother. 2007;51(8):2716–9.PubMedCrossRef

15.

Goldstein EJC, Citron DM, Sears P, et al. Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection. Antimicrob Agents Chemother. 2011;55(11):5194–9.PubMedCrossRef

16.

Karlowsky JA, Laing NM, Zhanel GG. In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile. Antimicrob Agents Chemother. 2008;52(11):4163–5.PubMedCrossRef

17.

Liao C-H, Ko W-C, Lu J-J, et al. Characterizations of clinical isolates of Clostridium difficile by toxin genotypes and by susceptibility to 12 antimicrobial agents, including fidaxomicin (OPT-80) and rifaximin: a multicenter study in Taiwan. Antimicrob Agents Chemother. 2012;56(7):3943–9.PubMedCrossRef

18.

Ackermann G, Loffler B, Adler D, et al. In vitro activity of OPT-80 against Clostridium difficile. Antimicrob Agents Chemother. 2004;48(6):2280–2.PubMedCrossRef

19.

Credito KL, Appelbaum PC. Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species. Antimicrob Agents Chemother. 2004;48(11):4430–4.PubMedCrossRef

20.

Artsimovitch I, Seddon J, Sears P. Fidaxomicin is an inhibitor of the initiation of bacterial RNA synthesis. Clin Infect Dis. 2012;55(Suppl 2):S127–31.PubMedCrossRef

21.

Seddon J, Babakhani F, Sears P. Mutant prevention concentration of fidaxomicin for Clostridium difficile [abstract no. A-1274 plus poster]. Interscience Conference on Antimicrobial Agents and Chemotherapy; 9–12 Sep 2012; San Francisco (CA).

22.

Babakhani F, Seddon J, Artsimovitch I, et al. Comparative microbiology of transcription inhibitors fidaxomicin and the rifamycins in Clostridium difficile [abstract no. 824 plus poster]. Infectious Diseases Week: Meeting of the Infectious Diseases Society of America; 17–21 Oct 2012; San Diego (CA).

23.

Seddon J, Xie l, Xie L, et al. Fidaxomicin molecular modeling and consequences for reduced-susceptibility mutants [abstract no. 23 plus poster]. 11th Biannual Congress of the Anaerobe Society of America; 27 Jun–1 Jul 2012; San Francisco (CA).

24.

Seddon J, Xie L, Xie L, et al. Molecular modeling of OP-1118 metabolite in Clostridium difficile RNA polymerase and comparison with fidaxomicin [poster no. 1195]. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 10–13 Sep 2013; Denver (CO).

25.

Babakhani F, Bouillaut L, Gomez A, et al. Fidaxomicin inhibits spore production in Clostridium difficile. Clin Infect Dis. 2012;55(Suppl 2):S162–9.PubMedCrossRef

26.

Allen CA, Babakhani F, Sears P, et al. Both fidaxomicin and vancomycin inhibit outgrowth of Clostridium difficile spores. Antimicrob Agents Chemother. 2013;57(1):664–7.PubMedCrossRef

27.

Chilton CH, Crowther GS, Todhunter SL, et al. Fidaxomicin persistence in an in-vitro human gut model, and adherence to Clostridium difficile spores [abstract no. P1129]. 23rd European Congress of Clinical Microbiology and Infectious Diseases; 27–30 Apr 2013; Berlin.

28.

Heeg D, Kuehne SA, Dempster AW, et al. Analysis of spore formation, germination and outgrowth of six clinically-relevant Clostridium difficile polymerase chain reaction (PCR)-ribotypes challenged with fidaxomicin [abstract no. P1140]. 23rd European Congress of Clinical Microbiology and Infectious Diseases; 27–30 Apr 2013; Berlin.

29.

Babakhani F, Bouillaut L, Sears P, et al. Fidaxomicin inhibits toxin production in Clostridium difficile. J Antimicrob Chemother. 2013;68(3):515–22.PubMedCrossRef

30.

Cornely OA, Crook DW, Esposito R, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis. 2012;12(4):281–9.PubMedCrossRef

31.

Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011;364(5):422–31.PubMedCrossRef

32.

Optimer Pharmaceuticals Inc. Dificid^® (fidaxomicin) tablets: US prescribing information. 2013. http://www.vibativ.com/docs/VIBATIV_PI_Final.pdf. Accessed 27 Jul 2013.

33.

European Medicines Agency. Dificlir 200 mg film-coated tablets: summary of product characteristics. 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002087/WC500119705.pdf. Accessed 27 Jul 2013.

34.

Goldstein EJC, Babakhani F, Citron DM. Antimicrobial activities of fidaxomicin. Clin Infect Dis. 2012;55(Suppl 2):S143–8.PubMedCrossRef

35.

DuPont HL. The search for effective treatment of Clostridium difficile infection. N Engl J Med. 2011;364(5):473–5.PubMedCrossRef

36.

Louie TJ, Emery J, Krulicki W, et al. OPT-80 eliminates Clostridium difficile and is sparing of Bacteroides species during treatment of C. difficile infection. Antimicrob Agents Chemother. 2009;53(1):261–3.PubMedCrossRef

37.

Babakhani F, Gomez A, Robert N, et al. Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile. J Med Microbiol. 2011;60(8):1213–7.PubMedCrossRef

38.

Babakhani F, Gomez A, Robert N, et al. Postantibiotic effect of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile. Antimicrob Agents Chemother. 2011;55(9):4427–9.PubMedCrossRef

39.

Babakhani F, Seddon J, Robert N, et al. Effects of inoculum, pH, and cations on the in vitro activity of fidaxomicin (OPT-80, PAR-101) against Clostridium difficile. Antimicrob Agents Chemother. 2010;54(6):2674–6.PubMedCrossRef

40.

Louie TJ, Cannon K, Byrne B, et al. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis. 2012;55(Suppl 2):S132–42.PubMedCrossRef

41.

Nerandzic MM, Mullane K, Miller MA, et al. Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection. Clin Infect Dis. 2012;55(Suppl 2):S121–6.PubMedCrossRef

42.

Tannock GW, Munro K, Taylor C, et al. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology. 2010;156(Pt 11):3354–9.PubMedCrossRef

43.

Babakhani F, Robert N, Seddon J, et al. Development of resistance in C. difficile with fidaxomicin, vancomycin, and rifaximin [abstract no. P2290]. Clin Microbiol Infect. 2012;18(Suppl 3):672.

44.

Seddon J, Babakhani F, Gomez A, et al. RNA polymerase target modification in Clostridium difficile with reduced susceptibility to fidaxomicin [abstract no. C1-631]. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; 17–20 Sep 2011; Chicago (IL).

45.

Eyre D, Babakhani F, Griffiths D, et al. Whole genome sequencing demonstrates fidaxomicin prevents Clostridium difficile relapse and reinfection [poster no. 1409]. Infectious Diseases Week Meeting; 4–6 Oct 2013; San Francisco (CA).

46.

Syndman DR, McDermott LA, Jacobus NV, et al. Two years of surveillance for the susceptibility and epidemiology of Clostridium difficile associated diarrheal isolates [poster no. C1-051]. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 10–13 Sep 2013; Denver (CO).

47.

Sears P, Crook DW, Louie TJ, et al. Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection. Clin Infect Dis. 2012;55(Suppl 2):S116–20.PubMedCrossRef

48.

Louie T, Miller M, Donskey C, et al. Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrob Agents Chemother. 2009;53(1):223–8.PubMedCrossRef

49.

Shue YK, Sears PS, Shangle S, et al. Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses. Antimicrob Agents Chemother. 2008;52(4):1391–5.PubMedCrossRef

50.

Lewis W, Sears SP. Minimal impact of food on the pharmacokinetics of oral fidaxomicin [abstract no. A2-042]. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; 17–20 Sep 2011; Chicago (IL).

51.

Sears P, O’Gorman MA, Otley A, et al. Fidaxomicin pharmacokinetics in children with Clostridium difficile infection: similar to adults [poster]. Infectious Diseases Week Meeting; 4–6 Oct 2013; San Francisco (CA).

52.

Lewis W, Tang M, Sears PS. Minimal effect of fidaxomicin on digoxin pharmacokinetics [abstract no. A2-043]. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; 17–20 Sep 2011; Chicago (IL).

53.

Lewis W, Sears PS. Coadministration of fidaxomicin does not impact the pharmacokinetics of CYP substrates omeprazole, warfarin, or midazolam [abstract no. A2-044]. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; 17–20 Sep 2011; Chicago (IL).

54.

Lewis W, Sears PS. Effect of cyclosporine on the pharmacokinetics of fidaxomicin [abstract no. A2-045]. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; 17–20 Sep 2011; Chicago (IL).

55.

Louie TJ, Miller MA, Crook DW, et al. Effect of age on treatment outcomes in Clostridium difficile infection. J Am Geriatr Soc. 2013;61(2):222–30.PubMedCrossRef

56.

Petrella LA, Sambol SP, Cheknis A, et al. Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain. Clin Infect Dis. 2012;55(3):351–7.PubMedCrossRef

57.

Crook DW, Walker AS, Kean Y, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials. Clin Infect Dis. 2012;55(Suppl 2):S93–103.PubMedCrossRef

58.

Cornely OA, Miller MA, Louie TJ, et al. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin Infect Dis. 2012;55(Suppl 2):S154–61.PubMedCrossRef

59.

Figueroa I, Johnson S, Sambol SP, et al. Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin. Clin Infect Dis. 2012;55(Suppl 2):S104–9.PubMedCrossRef

60.

Mullane KM, Miller MA, Weiss K, et al. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. [Erratum appears in Clin Infect Dis. 2011;53(12):1312]. Clin Infect Dis. 2011;53(5):440–7.PubMedCrossRef

61.

Mullane KM, Cornely OA, Crook DW, et al. Renal impairment and clinical outcomes of Clostridium difficile infection in two randomized trials. Am J Nephrol. 2013;38(1):1–11.PubMedCrossRef

62.

Golan Y, Louie T, Weiss K, et al. Clostridium difficile recurrence, alcohol consumption, and the effect of fidaxomicin vs vancomycin [abstract no. P1968]. Clin Microbiol Infect. 2011;17(Suppl 4):S577.

63.

Weiss K, Louie T, Miller MA, et al. Effect of proton pump inhibitors (PPI) and H2 receptor antagonists (HR2A) on response to therapy with fidaxomicin or vancomycin in hospitalized patients with Clostridium difficile infection [poster]. Arizon Pharmacy Alliance Health-System Academy Conference; 14 Apr 2012; Mesa (AZ).

64.

Alraddadi B, Epstein L, Syndham DR, et al. Recurrence of C. difficile infection (CDI): a risk-stratified analysis of fidaxomicin vs vancomycin [poster no. 317]. Meeting of the Infectious Diseases Society of America; 17–21 Oct 2012; San Diego (CA).

65.

Babakhani F, Eyre D, Figueroa I, et al. Comparison of strain typing results of Clostridium difficile isolates from subjects with recurrence of infection during fidaxomicin (FDX) phase 3 trials [poster no. D-1674]. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 10–13 Sep 2013; Denver (CO).

66.

Cornely OA, Miller MA, Fantin B, et al. Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin. J Clin Oncol. 2013;31(19):2493–9.PubMedCrossRef

67.

Alowayesh MS, Holdford D, Harpe SE. Decision analysis model evaluating the cost-effectiveness of fidaxomicin and vancomycin in the treatment of Clostridium difficile infection (CDI) from a hospital perspective [abstract no. PIN35]. Value Health. 2012;15(4):A243.CrossRef

68.

Bartsch SM, Umscheid CA, Fishman N. Is fidaxomicin worth the cost? An economic analysis. Clin Infect Dis. 2013;57(4):555–61.PubMedCrossRef

69.

Madkour N, Bounthavong M, Hsu DI. A comparison of the cost-effectiveness of fidaxomicin, metronidazole, and vancomycin, in the treatment of Clostridium difficile-associated disease [abstract no. PG121]. Value Health. 2012;15(4):A138–9.CrossRef

70.

Stranges PM, Hutton DW, Collins CD. Cost-effectiveness analysis evaluating fidaxomicin versus oral vancomycin for the treatment of Clostridium difficile infection in the United States. Value Health. 2013;16(2):297–304.PubMedCrossRef

71.

Wagner M, Lavoie L, Goetghebeur M. Clinical and economic consequences of vancomycin and fidaxomicin for the treatment of Clostridium difficile infection in Canada [abstract no. K-473]. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 9–12 Sep 2012; San Francisco (CA).

72.

Van Nispen tot Pannerden CMF, Verbon A, Kuipers EJ. Recurrent Clostridium difficile infection: what are the treatment options? Drugs. 2011;71(7):853–68.PubMedCrossRef

73.

Szabo SM, Levy AR, Lozano-Ortega G, et al. Incremental length of stay and costs associated with hospitalization for Clostridium difficile infection in Canada [poster]. Infectious Diseases Week Meeting; 2–6 Oct 2013; San Francisco (CA).

74.

Levy AR, Szabo SM, Lozano-Ortega G, et al. The economic burden of Clostridium difficile infection in Canada [poster]. Infectious Diseases Week Meeting; 2–6 Oct 2013; San Francisco (CA).

75.

Drozd EM, Braithwaite S, Shah H, et al. The impact of Clostridium difficile-associated diarrhea on the health care utilization of older and chronically ill patients [poster no. 1383]. Infectious Diseases Week Meeting; 2–6 Oct 2013; San Francisco (CA).

76.

Magee G, Brown H, Strauss ME, et al. The economic burden of Clostridium difficile-associated diarrhea: a retrospective study of acute care hospital inpatients, 2009–2011 [poster]. Infectious Diseases Week Meeting; 2–6 Oct 2013; San Francisco (CA).

Titel: Fidaxomicin: A Review of Its Use in Patients with Clostridium difficile Infection
verfasst von: Lesley J. Scott
Publikationsdatum: 01.10.2013
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 15/2013
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.1007/s40265-013-0134-z

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 15/2013

Optimal Sequencing of Anti-HER2 Therapy Throughout the Continuum of HER2-Positive Breast Cancer: Evidence and Clinical Considerations

Pharmacology of the New P2Y12 Receptor Inhibitors: Insights on Pharmacokinetic and Pharmacodynamic Properties

A Systematic Review of Pharmacological Pain Management in Multiple Sclerosis

Enzalutamide: A Review of Its Use in Metastatic, Castration-Resistant Prostate Cancer

Targeting Hyperglycaemia with Anti-Obesity Drugs: Time for a Paradigm Shift?

β-Adrenoceptor Modulation in Chronic Obstructive Pulmonary Disease: Present and Future Perspectives